Lisata Therapeutics, Inc. (LSTA) 10-Year Financial Performance & Capital Metrics

LSTA • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutLisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Show more

Revenue $1M
EBITDA -$22M +12.9%
Net Income -$20M +4.1%
EPS (Diluted) -2.40 +7.0%
Gross Margin 100%
EBITDA Margin -2223.5%
Operating Margin -2240.9%
Net Margin -1998.5%
ROE -51.77% -41.9%
ROIC -86.83% -35.4%
Debt/Equity 0.00 +33.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-25.08%

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM12.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.14%

ROCE

10Y Avg-62.21%

5Y Avg-58.57%

3Y Avg-58.34%

Latest-57.83%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	22.49M	35.28M	0	0	0	0	0	0	0	1M
Revenue Growth %	0.25%	0.57%	-1%	-	-	-	-	-	-	-
Cost of Goods Sold+	20.16M	450.27K	372K	225K	65K	63K	0	0	0	0
COGS % of Revenue	0.9%	0.01%	-	-	-	-	-	-	-	-
Gross Profit+	2.33M	4.15M	-372K	-225K	-65K	-63K	0	0	0	1M
Gross Margin %	0.1%	0.12%	-	-	-	-	-	-	-	1%
Gross Profit Growth %	0.03%	0.78%	-1.09%	0.4%	0.71%	0.03%	1%	-	-	-
Operating Expenses+	53.91M	35.48M	27.59M	16.99M	20.09M	19.14M	29.05M	57.6M	25.71M	23.41M
OpEx % of Revenue	2.4%	1.01%	-	-	-	-	-	-	-	23.41%
Selling, General & Admin	30.01M	12.8M	11.75M	9.39M	9.29M	9.89M	11.47M	14.14M	12.97M	12.07M
SG&A % of Revenue	1.33%	0.36%	-	-	-	-	-	-	-	12.07%
Research & Development	23.9M	15.11M	17.14M	7.59M	13.5M	9.25M	17.58M	43.46M	12.73M	11.33M
R&D % of Revenue	1.06%	0.43%	-	-	-	-	-	-	-	11.33%
Other Operating Expenses	0	21.96K	-1.3M	824K	-2.7M	0	0	0	0	0
Operating Income+	-51.58M	-31.34M	-27.59M	-16.99M	-20.09M	-19.14M	-29.05M	-57.6M	-25.71M	-22.41M
Operating Margin %	-2.29%	-0.89%	-	-	-	-	-	-	-	-22.41%
Operating Income Growth %	0.11%	0.39%	0.12%	0.38%	-0.18%	0.05%	-0.52%	-0.98%	0.55%	0.13%
EBITDA+	-48.89M	-30.89M	-27.22M	-16.76M	-20.03M	-19.08M	-29M	-57.53M	-25.52M	-22.23M
EBITDA Margin %	-2.17%	-0.88%	-	-	-	-	-	-	-	-22.23%
EBITDA Growth %	0.12%	0.37%	0.12%	0.38%	-0.19%	0.05%	-0.52%	-0.98%	0.56%	0.13%
D&A (Non-Cash Add-back)	2.69M	450.27K	372K	225K	65K	63K	55K	69K	189K	174K
EBIT	-96.13M	-29.48M	-27.59M	-16.99M	-20.09M	-19.14M	-29.05M	-57.6M	-25.71M	-22.41M
Net Interest Income+	-2.13M	0	0	0	740K	132K	151K	1.05M	2.72M	1.88M
Interest Income	0	0	0	0	740K	132K	151K	1.05M	2.72M	1.88M
Interest Expense	2.13M	1.86M	377.77K	5K	0	0	0	0	0	0
Other Income/Expense	-46.68M	-1.76M	-105K	819K	740K	132K	76K	897K	2.54M	1.63M
Pretax Income+	-98.25M	-31.26M	-27.7M	-16.17M	-19.35M	-19.01M	-28.97M	-56.7M	-23.17M	-20.78M
Pretax Margin %	-4.37%	-0.89%	-	-	-	-	-	-	-	-20.78%
Income Tax+	-17.24M	138.04K	-11.53M	-1K	0	-10.87M	-1.51M	-2.48M	-2.33M	-798K
Effective Tax Rate %	0.82%	1.04%	-0.83%	1%	1.04%	0.43%	0.95%	0.96%	0.9%	0.96%
Net Income+	-80.89M	-32.66M	22.98M	-16.17M	-20.1M	-8.15M	-27.47M	-54.23M	-20.84M	-19.98M
Net Margin %	-3.6%	-0.93%	-	-	-	-	-	-	-	-19.98%
Net Income Growth %	-0.47%	0.6%	1.7%	-1.7%	-0.24%	0.59%	-2.37%	-0.97%	0.62%	0.04%
Net Income (Continuing)	-81.01M	-31.26M	-16.17M	-16.17M	-19.35M	-8.14M	-27.47M	-54.23M	-20.84M	-19.98M
Discontinued Operations	0	-1.64M	38.97M	0	0	0	0	0	0	0
Minority Interest	-429.71K	-817.43K	-318.28K	-272K	-263K	-254K	-254K	-254K	-254K	-254K
EPS (Diluted)+	-250.12	-74.81	38.43	-25.03	-29.20	-7.91	-7.45	-10.47	-2.58	-2.40
EPS Growth %	0%	0.7%	1.51%	-1.65%	-0.17%	0.73%	0.06%	-0.41%	0.75%	0.07%
EPS (Basic)	-250.12	-74.81	38.43	-25.03	-29.20	-7.91	-7.45	-10.47	-2.58	-2.40
Diluted Shares Outstanding	323.39K	436.55K	597.93K	645.93K	688.33K	1.03M	3.69M	5.18M	8.07M	8.33M
Basic Shares Outstanding	323.39K	436.55K	633.87K	645.93K	688.33K	1.03M	3.69M	5.18M	8.07M	8.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.27M	24.65M	61.11M	44.11M	25.97M	35.33M	96.18M	71.88M	53.92M	34.58M
Cash & Short-Term Investments	20.32M	14.71M	55.08M	43.05M	25.16M	34.57M	94.97M	69.23M	50.53M	31.25M
Cash Only	20.32M	14.71M	29.16M	10.3M	14.03M	16.51M	24.65M	32.15M	22.59M	16.21M
Short-Term Investments	0	0	25.92M	32.75M	11.13M	18.06M	70.32M	37.07M	27.94M	15.04M
Accounts Receivable	2.57M	138.77K	234.46K	0	0	0	0	0	0	900K
Days Sales Outstanding	41.65	1.44	-	-	-	-	-	-	-	328.5
Inventory	2.91M	3.58M	5M	0	0	0	0	0	0	0
Days Inventory Outstanding	52.72	2.9K	4.91K	-	-	-	-	-	-	-
Other Current Assets	2.91M	15.53M	4.77M	0	0	0	0	2.65M	3.39M	2.43M
Total Non-Current Assets+	27.93M	27.18M	2.27M	474K	1.18M	671K	826K	1.16M	770K	424K
Property, Plant & Equipment	17.06M	17.15M	256.9K	165K	100K	57K	62K	296K	175K	72K
Fixed Asset Turnover	1.32x	2.06x	-	-	-	-	-	-	-	13.89x
Goodwill	7.01M	7.01M	0	0	0	0	0	0	0	0
Intangible Assets	2.88M	2.31M	0	0	0	0	0	334K	263K	192K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	976.77K	713.45K	1.43M	309K	1.08M	614K	764K	528K	332K	160K
Total Assets+	57.21M	51.83M	63.38M	44.58M	27.15M	36M	97.01M	73.03M	54.69M	35M
Asset Turnover	0.39x	0.68x	-	-	-	-	-	-	-	0.03x
Asset Growth %	-0.55%	-0.09%	0.22%	-0.3%	-0.39%	0.33%	1.69%	-0.25%	-0.25%	-0.36%
Total Current Liabilities+	21.02M	19.5M	9.31M	5.62M	5.98M	3.51M	4.52M	6.38M	6.59M	5.61M
Accounts Payable	4.11M	2.23M	1.34M	762K	1.49M	1.02M	1.93M	2.65M	2.42M	1.28M
Days Payables Outstanding	74.37	1.8K	1.32K	1.24K	8.37K	5.91K	-	-	-	-
Short-Term Debt	5.36M	3.69M	159K	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	3.43M	8.76M	4.68M	3.1M	0	0	0	0	0	0
Current Ratio	1.39x	1.26x	6.56x	7.85x	4.35x	10.08x	21.27x	11.26x	8.18x	6.16x
Quick Ratio	1.25x	1.08x	6.02x	7.85x	4.35x	10.08x	21.27x	11.26x	8.18x	6.16x
Cash Conversion Cycle	20	1.1K	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	12.91M	28.27M	3.87M	1.51M	624K	254K	485K	327K	210K	72K
Long-Term Debt	11.41M	2.68M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	624K	254K	485K	305K	0	0
Deferred Tax Liabilities	932.66K	1.07M	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	562K	19.92M	3.87M	1.51M	0	0	0	22K	210K	72K
Total Liabilities	33.92M	47.77M	13.19M	7.13M	6.6M	3.76M	5.01M	6.71M	6.8M	5.68M
Total Debt+	16.78M	6.79M	159.18K	0	978K	624K	714K	485K	168K	137K
Net Debt	-3.54M	-7.91M	-29M	-10.3M	-13.05M	-15.89M	-23.93M	-31.67M	-22.43M	-16.07M
Debt / Equity	0.72x	1.67x	0.00x	-	0.05x	0.02x	0.01x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-24.24x	-16.87x	-73.04x	-3397.40x	-	-	-	-	-	-
Total Equity+	23.28M	4.07M	50.19M	37.45M	20.55M	32.24M	92M	66.32M	47.89M	29.32M
Equity Growth %	-0.6%	-0.83%	11.34%	-0.25%	-0.45%	0.57%	1.85%	-0.28%	-0.28%	-0.39%
Book Value per Share	72.00	9.32	83.94	57.98	29.86	31.33	24.95	12.80	5.93	3.52
Total Shareholders' Equity	23.71M	4.88M	50.51M	37.73M	20.82M	32.5M	92.25M	66.58M	48.15M	29.57M
Common Stock	56.73K	8.21K	9.48K	10K	11K	19K	4K	8K	8K	8K
Retained Earnings	-372.13M	-404.79M	-381.81M	-397.98M	-417.4M	-425.55M	-453.02M	-507.24M	-528.08M	-548.07M
Treasury Stock	-707.64K	-707.64K	-708K	-708K	-708K	-708K	-708K	-708K	-708K	-708K
Accumulated OCI	486	0	-27.98K	-32K	2K	-13K	-70K	-29K	-42K	-81K
Minority Interest	-429.71K	-817.43K	-318.28K	-272K	-263K	-254K	-254K	-254K	-254K	-254K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-39.26M	-23.67M	-20.88M	-19.99M	-18.88M	-8.82M	-22.25M	-21.17M	-20.03M	-19.36M
Operating CF Margin %	-1.75%	-0.67%	-	-	-	-	-	-	-	-19.36%
Operating CF Growth %	0.16%	0.4%	0.12%	0.04%	0.06%	0.53%	-1.52%	0.05%	0.05%	0.03%
Net Income	-81.01M	-33.31M	-16.17M	-16.17M	-19.35M	-8.14M	-27.47M	-54.23M	-20.84M	-19.98M
Depreciation & Amortization	2.69M	2.74M	372K	225K	65K	63K	55K	69K	189K	174K
Stock-Based Compensation	9.75K	2.6M	1.96M	2.45M	1.29M	1.26M	2M	2.64M	2.04M	1.65M
Deferred Taxes	-17.24M	138.04K	-12.1M	0	0	0	0	0	0	0
Other Non-Cash Items	-8.51M	591.31K	-86.29K	-1.15M	232K	307K	2.51M	31.18M	-957K	-325K
Working Capital Changes	2.45M	3.56M	5.15M	-5.35M	-1.12M	-2.32M	647K	-831K	-462K	-873K
Change in Receivables	545.17K	-325.62K	-95.69K	0	0	0	0	0	0	-900K
Change in Inventory	1.16M	269.07K	-571.61K	0	0	0	0	0	0	0
Change in Payables	79.26K	-48.7K	5.67M	-5.9M	-1.86M	-2.84M	1.25M	-223K	88K	-995K
Cash from Investing+	3.8M	-2.85M	41.27M	-4.71M	21.43M	-7.28M	-54.9M	28.91M	10.1M	13.23M
Capital Expenditures	-3.19M	-2.85M	-135.28K	-134K	0	-20K	-60K	-285K	0	0
CapEx % of Revenue	0.14%	0.08%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	6.98K	-1.75M	-188.79K	2.55M	0	-7.26K	-54.84K	0	0	0
Cash from Financing+	36.6M	20.9M	-931.77K	824K	1.18M	18.58M	85.28M	-224K	385K	-206K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-15M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	18.92M	-419K	-48K	-130K	-148K	-224K	-267K	64K	-274K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-42.44M	-26.52M	-21.01M	-20.12M	-18.88M	-8.84M	-22.3M	-21.45M	-20.03M	-19.36M
FCF Margin %	-1.89%	-0.75%	-	-	-	-	-	-	-	-19.36%
FCF Growth %	0.16%	0.38%	0.21%	0.04%	0.06%	0.53%	-1.52%	0.04%	0.07%	0.03%
FCF per Share	-131.25	-60.74	-35.14	-31.15	-27.43	-8.59	-6.05	-4.14	-2.48	-2.32
FCF Conversion (FCF/Net Income)	0.49x	0.72x	-0.91x	1.24x	0.94x	1.08x	0.81x	0.39x	0.96x	0.97x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-198.84%	-238.8%	84.71%	-36.89%	-69.31%	-30.87%	-44.21%	-68.5%	-36.49%	-51.77%
Return on Invested Capital (ROIC)	-102.76%	-295.74%	-238.72%	-52.71%	-86.97%	-120.39%	-51.62%	-84.11%	-64.14%	-86.83%
Gross Margin	10.36%	11.76%	-	-	-	-	-	-	-	100%
Net Margin	-359.69%	-92.55%	-	-	-	-	-	-	-	-1998.5%
Debt / Equity	0.72x	1.67x	0.00x	-	0.05x	0.02x	0.01x	0.01x	0.00x	0.00x
Interest Coverage	-24.24x	-16.87x	-73.04x	-3397.40x	-	-	-	-	-	-
FCF Conversion	0.49x	0.72x	-0.91x	1.24x	0.94x	1.08x	0.81x	0.39x	0.96x	0.97x
Revenue Growth	25.36%	56.9%	-100%	-	-	-	-	-	-	-

Revenue by Segment

	2024
Reportable	1M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Lisata Therapeutics, Inc. (LSTA) reported $1.1M in revenue for fiscal year 2024. This represents a 89% decrease from $10.1M in 2011.

Lisata Therapeutics, Inc. (LSTA) grew revenue by 0.0% over the past year. Growth has been modest.

Lisata Therapeutics, Inc. (LSTA) reported a net loss of $18.2M for fiscal year 2024.

Dividend & Returns

Lisata Therapeutics, Inc. (LSTA) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.

Lisata Therapeutics, Inc. (LSTA) had negative free cash flow of $17.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Lisata Therapeutics, Inc. (LSTA) 10-Year Financial Performance & Capital Metrics

LSTA • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

Revenue $1M
EBITDA -$22M +12.9%
Net Income -$20M +4.1%
EPS (Diluted) -2.40 +7.0%
Gross Margin 100%
EBITDA Margin -2223.5%
Operating Margin -2240.9%
Net Margin -1998.5%
ROE -51.77% -41.9%
ROIC -86.83% -35.4%
Debt/Equity 0.00 +33.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-25.08%

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM12.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM15.14%

ROCE

10Y Avg-62.21%

5Y Avg-58.57%

3Y Avg-58.34%

Latest-57.83%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	22.49M	35.28M	0	0	0	0	0	0	0	1M
Revenue Growth %	0.25%	0.57%	-1%	-	-	-	-	-	-	-
Cost of Goods Sold+	20.16M	450.27K	372K	225K	65K	63K	0	0	0	0
COGS % of Revenue	0.9%	0.01%	-	-	-	-	-	-	-	-
Gross Profit+	2.33M	4.15M	-372K	-225K	-65K	-63K	0	0	0	1M
Gross Margin %	0.1%	0.12%	-	-	-	-	-	-	-	1%
Gross Profit Growth %	0.03%	0.78%	-1.09%	0.4%	0.71%	0.03%	1%	-	-	-
Operating Expenses+	53.91M	35.48M	27.59M	16.99M	20.09M	19.14M	29.05M	57.6M	25.71M	23.41M
OpEx % of Revenue	2.4%	1.01%	-	-	-	-	-	-	-	23.41%
Selling, General & Admin	30.01M	12.8M	11.75M	9.39M	9.29M	9.89M	11.47M	14.14M	12.97M	12.07M
SG&A % of Revenue	1.33%	0.36%	-	-	-	-	-	-	-	12.07%
Research & Development	23.9M	15.11M	17.14M	7.59M	13.5M	9.25M	17.58M	43.46M	12.73M	11.33M
R&D % of Revenue	1.06%	0.43%	-	-	-	-	-	-	-	11.33%
Other Operating Expenses	0	21.96K	-1.3M	824K	-2.7M	0	0	0	0	0
Operating Income+	-51.58M	-31.34M	-27.59M	-16.99M	-20.09M	-19.14M	-29.05M	-57.6M	-25.71M	-22.41M
Operating Margin %	-2.29%	-0.89%	-	-	-	-	-	-	-	-22.41%
Operating Income Growth %	0.11%	0.39%	0.12%	0.38%	-0.18%	0.05%	-0.52%	-0.98%	0.55%	0.13%
EBITDA+	-48.89M	-30.89M	-27.22M	-16.76M	-20.03M	-19.08M	-29M	-57.53M	-25.52M	-22.23M
EBITDA Margin %	-2.17%	-0.88%	-	-	-	-	-	-	-	-22.23%
EBITDA Growth %	0.12%	0.37%	0.12%	0.38%	-0.19%	0.05%	-0.52%	-0.98%	0.56%	0.13%
D&A (Non-Cash Add-back)	2.69M	450.27K	372K	225K	65K	63K	55K	69K	189K	174K
EBIT	-96.13M	-29.48M	-27.59M	-16.99M	-20.09M	-19.14M	-29.05M	-57.6M	-25.71M	-22.41M
Net Interest Income+	-2.13M	0	0	0	740K	132K	151K	1.05M	2.72M	1.88M
Interest Income	0	0	0	0	740K	132K	151K	1.05M	2.72M	1.88M
Interest Expense	2.13M	1.86M	377.77K	5K	0	0	0	0	0	0
Other Income/Expense	-46.68M	-1.76M	-105K	819K	740K	132K	76K	897K	2.54M	1.63M
Pretax Income+	-98.25M	-31.26M	-27.7M	-16.17M	-19.35M	-19.01M	-28.97M	-56.7M	-23.17M	-20.78M
Pretax Margin %	-4.37%	-0.89%	-	-	-	-	-	-	-	-20.78%
Income Tax+	-17.24M	138.04K	-11.53M	-1K	0	-10.87M	-1.51M	-2.48M	-2.33M	-798K
Effective Tax Rate %	0.82%	1.04%	-0.83%	1%	1.04%	0.43%	0.95%	0.96%	0.9%	0.96%
Net Income+	-80.89M	-32.66M	22.98M	-16.17M	-20.1M	-8.15M	-27.47M	-54.23M	-20.84M	-19.98M
Net Margin %	-3.6%	-0.93%	-	-	-	-	-	-	-	-19.98%
Net Income Growth %	-0.47%	0.6%	1.7%	-1.7%	-0.24%	0.59%	-2.37%	-0.97%	0.62%	0.04%
Net Income (Continuing)	-81.01M	-31.26M	-16.17M	-16.17M	-19.35M	-8.14M	-27.47M	-54.23M	-20.84M	-19.98M
Discontinued Operations	0	-1.64M	38.97M	0	0	0	0	0	0	0
Minority Interest	-429.71K	-817.43K	-318.28K	-272K	-263K	-254K	-254K	-254K	-254K	-254K
EPS (Diluted)+	-250.12	-74.81	38.43	-25.03	-29.20	-7.91	-7.45	-10.47	-2.58	-2.40
EPS Growth %	0%	0.7%	1.51%	-1.65%	-0.17%	0.73%	0.06%	-0.41%	0.75%	0.07%
EPS (Basic)	-250.12	-74.81	38.43	-25.03	-29.20	-7.91	-7.45	-10.47	-2.58	-2.40
Diluted Shares Outstanding	323.39K	436.55K	597.93K	645.93K	688.33K	1.03M	3.69M	5.18M	8.07M	8.33M
Basic Shares Outstanding	323.39K	436.55K	633.87K	645.93K	688.33K	1.03M	3.69M	5.18M	8.07M	8.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.27M	24.65M	61.11M	44.11M	25.97M	35.33M	96.18M	71.88M	53.92M	34.58M
Cash & Short-Term Investments	20.32M	14.71M	55.08M	43.05M	25.16M	34.57M	94.97M	69.23M	50.53M	31.25M
Cash Only	20.32M	14.71M	29.16M	10.3M	14.03M	16.51M	24.65M	32.15M	22.59M	16.21M
Short-Term Investments	0	0	25.92M	32.75M	11.13M	18.06M	70.32M	37.07M	27.94M	15.04M
Accounts Receivable	2.57M	138.77K	234.46K	0	0	0	0	0	0	900K
Days Sales Outstanding	41.65	1.44	-	-	-	-	-	-	-	328.5
Inventory	2.91M	3.58M	5M	0	0	0	0	0	0	0
Days Inventory Outstanding	52.72	2.9K	4.91K	-	-	-	-	-	-	-
Other Current Assets	2.91M	15.53M	4.77M	0	0	0	0	2.65M	3.39M	2.43M
Total Non-Current Assets+	27.93M	27.18M	2.27M	474K	1.18M	671K	826K	1.16M	770K	424K
Property, Plant & Equipment	17.06M	17.15M	256.9K	165K	100K	57K	62K	296K	175K	72K
Fixed Asset Turnover	1.32x	2.06x	-	-	-	-	-	-	-	13.89x
Goodwill	7.01M	7.01M	0	0	0	0	0	0	0	0
Intangible Assets	2.88M	2.31M	0	0	0	0	0	334K	263K	192K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	976.77K	713.45K	1.43M	309K	1.08M	614K	764K	528K	332K	160K
Total Assets+	57.21M	51.83M	63.38M	44.58M	27.15M	36M	97.01M	73.03M	54.69M	35M
Asset Turnover	0.39x	0.68x	-	-	-	-	-	-	-	0.03x
Asset Growth %	-0.55%	-0.09%	0.22%	-0.3%	-0.39%	0.33%	1.69%	-0.25%	-0.25%	-0.36%
Total Current Liabilities+	21.02M	19.5M	9.31M	5.62M	5.98M	3.51M	4.52M	6.38M	6.59M	5.61M
Accounts Payable	4.11M	2.23M	1.34M	762K	1.49M	1.02M	1.93M	2.65M	2.42M	1.28M
Days Payables Outstanding	74.37	1.8K	1.32K	1.24K	8.37K	5.91K	-	-	-	-
Short-Term Debt	5.36M	3.69M	159K	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	3.43M	8.76M	4.68M	3.1M	0	0	0	0	0	0
Current Ratio	1.39x	1.26x	6.56x	7.85x	4.35x	10.08x	21.27x	11.26x	8.18x	6.16x
Quick Ratio	1.25x	1.08x	6.02x	7.85x	4.35x	10.08x	21.27x	11.26x	8.18x	6.16x
Cash Conversion Cycle	20	1.1K	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	12.91M	28.27M	3.87M	1.51M	624K	254K	485K	327K	210K	72K
Long-Term Debt	11.41M	2.68M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	624K	254K	485K	305K	0	0
Deferred Tax Liabilities	932.66K	1.07M	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	562K	19.92M	3.87M	1.51M	0	0	0	22K	210K	72K
Total Liabilities	33.92M	47.77M	13.19M	7.13M	6.6M	3.76M	5.01M	6.71M	6.8M	5.68M
Total Debt+	16.78M	6.79M	159.18K	0	978K	624K	714K	485K	168K	137K
Net Debt	-3.54M	-7.91M	-29M	-10.3M	-13.05M	-15.89M	-23.93M	-31.67M	-22.43M	-16.07M
Debt / Equity	0.72x	1.67x	0.00x	-	0.05x	0.02x	0.01x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-24.24x	-16.87x	-73.04x	-3397.40x	-	-	-	-	-	-
Total Equity+	23.28M	4.07M	50.19M	37.45M	20.55M	32.24M	92M	66.32M	47.89M	29.32M
Equity Growth %	-0.6%	-0.83%	11.34%	-0.25%	-0.45%	0.57%	1.85%	-0.28%	-0.28%	-0.39%
Book Value per Share	72.00	9.32	83.94	57.98	29.86	31.33	24.95	12.80	5.93	3.52
Total Shareholders' Equity	23.71M	4.88M	50.51M	37.73M	20.82M	32.5M	92.25M	66.58M	48.15M	29.57M
Common Stock	56.73K	8.21K	9.48K	10K	11K	19K	4K	8K	8K	8K
Retained Earnings	-372.13M	-404.79M	-381.81M	-397.98M	-417.4M	-425.55M	-453.02M	-507.24M	-528.08M	-548.07M
Treasury Stock	-707.64K	-707.64K	-708K	-708K	-708K	-708K	-708K	-708K	-708K	-708K
Accumulated OCI	486	0	-27.98K	-32K	2K	-13K	-70K	-29K	-42K	-81K
Minority Interest	-429.71K	-817.43K	-318.28K	-272K	-263K	-254K	-254K	-254K	-254K	-254K

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-39.26M	-23.67M	-20.88M	-19.99M	-18.88M	-8.82M	-22.25M	-21.17M	-20.03M	-19.36M
Operating CF Margin %	-1.75%	-0.67%	-	-	-	-	-	-	-	-19.36%
Operating CF Growth %	0.16%	0.4%	0.12%	0.04%	0.06%	0.53%	-1.52%	0.05%	0.05%	0.03%
Net Income	-81.01M	-33.31M	-16.17M	-16.17M	-19.35M	-8.14M	-27.47M	-54.23M	-20.84M	-19.98M
Depreciation & Amortization	2.69M	2.74M	372K	225K	65K	63K	55K	69K	189K	174K
Stock-Based Compensation	9.75K	2.6M	1.96M	2.45M	1.29M	1.26M	2M	2.64M	2.04M	1.65M
Deferred Taxes	-17.24M	138.04K	-12.1M	0	0	0	0	0	0	0
Other Non-Cash Items	-8.51M	591.31K	-86.29K	-1.15M	232K	307K	2.51M	31.18M	-957K	-325K
Working Capital Changes	2.45M	3.56M	5.15M	-5.35M	-1.12M	-2.32M	647K	-831K	-462K	-873K
Change in Receivables	545.17K	-325.62K	-95.69K	0	0	0	0	0	0	-900K
Change in Inventory	1.16M	269.07K	-571.61K	0	0	0	0	0	0	0
Change in Payables	79.26K	-48.7K	5.67M	-5.9M	-1.86M	-2.84M	1.25M	-223K	88K	-995K
Cash from Investing+	3.8M	-2.85M	41.27M	-4.71M	21.43M	-7.28M	-54.9M	28.91M	10.1M	13.23M
Capital Expenditures	-3.19M	-2.85M	-135.28K	-134K	0	-20K	-60K	-285K	0	0
CapEx % of Revenue	0.14%	0.08%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	6.98K	-1.75M	-188.79K	2.55M	0	-7.26K	-54.84K	0	0	0
Cash from Financing+	36.6M	20.9M	-931.77K	824K	1.18M	18.58M	85.28M	-224K	385K	-206K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-15M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	18.92M	-419K	-48K	-130K	-148K	-224K	-267K	64K	-274K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-42.44M	-26.52M	-21.01M	-20.12M	-18.88M	-8.84M	-22.3M	-21.45M	-20.03M	-19.36M
FCF Margin %	-1.89%	-0.75%	-	-	-	-	-	-	-	-19.36%
FCF Growth %	0.16%	0.38%	0.21%	0.04%	0.06%	0.53%	-1.52%	0.04%	0.07%	0.03%
FCF per Share	-131.25	-60.74	-35.14	-31.15	-27.43	-8.59	-6.05	-4.14	-2.48	-2.32
FCF Conversion (FCF/Net Income)	0.49x	0.72x	-0.91x	1.24x	0.94x	1.08x	0.81x	0.39x	0.96x	0.97x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-198.84%	-238.8%	84.71%	-36.89%	-69.31%	-30.87%	-44.21%	-68.5%	-36.49%	-51.77%
Return on Invested Capital (ROIC)	-102.76%	-295.74%	-238.72%	-52.71%	-86.97%	-120.39%	-51.62%	-84.11%	-64.14%	-86.83%
Gross Margin	10.36%	11.76%	-	-	-	-	-	-	-	100%
Net Margin	-359.69%	-92.55%	-	-	-	-	-	-	-	-1998.5%
Debt / Equity	0.72x	1.67x	0.00x	-	0.05x	0.02x	0.01x	0.01x	0.00x	0.00x
Interest Coverage	-24.24x	-16.87x	-73.04x	-3397.40x	-	-	-	-	-	-
FCF Conversion	0.49x	0.72x	-0.91x	1.24x	0.94x	1.08x	0.81x	0.39x	0.96x	0.97x
Revenue Growth	25.36%	56.9%	-100%	-	-	-	-	-	-	-

Revenue by Segment

	2024
Reportable	1M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

Lisata Therapeutics, Inc. (LSTA) reported $1.1M in revenue for fiscal year 2024. This represents a 89% decrease from $10.1M in 2011.

Lisata Therapeutics, Inc. (LSTA) grew revenue by 0.0% over the past year. Growth has been modest.

Lisata Therapeutics, Inc. (LSTA) reported a net loss of $18.2M for fiscal year 2024.

Dividend & Returns

Lisata Therapeutics, Inc. (LSTA) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.

Lisata Therapeutics, Inc. (LSTA) had negative free cash flow of $17.3M in fiscal year 2024, likely due to heavy capital investments.